Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment. In this review, we attempt to give a brief overview of the animal models of PD currently used, with a more comprehensive focus on the advantages and disadvantages presented by their use in the nonhuman primate. In particular, discussion addresses the 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydopyridine (MPTP), rotenone, paraquat, and maneb parkinsonian models. Additionally, the role of primate PD models in the development of novel therapies, such as trophic factor delivery, grafting, and deep brain stimulation, are described. Finally, the contribution of primate PD models to our understanding of the etiology and pathology of human PD is discussed.
a means of early diagnosis for prevention of further DA cell human disease so as to have predictive validity in PD patients when testing novel therapeutic strategies. This loss. While nigrostriatal degeneration is a central pathology associated with the cardinal signs of PD, other regions review will attempt to address the viability of in vivo animal models, especially current nonhuman primate clearly degenerate and nigrostriatal degeneration may actually occur relatively late in the disease process (17) . models, to accurately mimic PD, assess their impact on the evaluation of novel therapies, and highlight the in-Treating Parkinson' Disease sights into PD that have been obtained from nonhuman primate research. Treatment for PD has focused on restoring DA levels in the striatum via several approaches, including phar-PARKINSON MODELS macological replacement of DA (3), surgical transplan-6-Hydroxydopamine tation of DA neurons (16), and gene therapy (89) . Electrolytic lesions (87) and deep brain stimulation (60) have
The discovery of the neurotoxin 6-hydroxydopamine (6-OHDA) allowed for the selective degeneration of do-been employed to restore normal levels of electrophysiological activity to overactive sites in basal ganglia cir-paminergic and noradrenergic neurons, and presented the first real in vivo animal model of PD (119) . Prefer-cuitry, with the ultimate goal of enhancing the drive of the thalamocortical pathway. entially taken up by catecholaminergic neurons, the intracellular metabolism of 6-OHDA results in the pro-Pharmacological agents used for symptomatic relief in PD commonly target DA receptors, specifically the duction of free radicals, hydrogen peroxide, and the destruction of neurons due to oxidative stress (102) . D2 DA receptors (3) . Decades after its introduction, levodopa (L-DOPA) remains the gold standard against 6-OHDA does not cross the blood-brain barrier and therefore must be delivered via stereotaxic surgery to which all others therapies are compared. L-DOPA is the biochemical precursor to DA. It readily crosses the the ventricular system or directly to the neurons and axons of the nigra and/or striatum. While ventricular deliv-blood-brain barrier and is converted to DA in the brain. Unfortunately, in addition to its significant therapeutic ery does allow for bilateral lesions, representative of all but the earliest stages of human PD, it presents the prob-benefit, L-DOPA use is accompanied by drug-induced dyskinesias. In the present era, patients treated with lev-lem of cell loss to other areas not classically associated with PD (e.g., hypothalamic DA neurons). To prevent odopa therapy for 4-6 years have a risk of developing dyskinesias of approximately 40% (1) . Dyskinesias are uptake into noradrenergic terminals, ventricular delivery of 6-OHDA is accompanied by the selective uptake in-a severe side effect characterized by uncontrollable hyperkinetic movements and dystonia due to unregulated hibitor, des-methylimipramine (DMI) (98). Additionally, comprehensive bilateral lesions produce a severe syn-levels of DA within the basal ganglia (49) . Additionally, specific D2 receptor agonists, partial D2 agonists, D2/ drome that includes a host of non-PD-relevant side effects such as aphagia, adipsia, and lethargy that can con-D3 agonists, NMDA antagonists, serotonin antagonists, opioid receptor antagonists, COMT inhibitors (that pre-found analyses of therapies for PD. Most often, 6-OHDA has been used to produce uni-vent alternative routes of DA degradation), anticholinergics, and even antiepileptics have been used therapeuti-lateral lesions in rodent models of PD, although it has been used in limited nonhuman primate studies. Stereo-cally (3) . Many of these alternative drug choices are associated with a lower incidence of dyskinesias but are taxic surgical delivery of 6-OHDA directly to nigrostriatal neurons, the medial forebrain bundle, or striatum pro-not as effective as L-DOPA on their own. These side effects and shortcomings of pharmacological treatments vides a specific lesion of the nigrostriatal pathway. By varying the placement and severity of the lesion, specific have led to attempts to develop new therapies for PD. This review will cover several experimental treatment components of the nigrostriatal pathway involved in PD symptomology can be selectively analyzed. Delivery of options being examined in primate models of PD including gene therapy (57) , engraftment strategies (4), and 6-OHDA to the medial forebrain bundle and/or SN can effectively diminish striatal dopamine by over 90%, ac-brain stimulation (26) .
curately representing the late stages of parkinsonian pa-Modeling Parkinson' Disease tients (106) . Furthermore, this delivery of 6-OHDA to the medial forebrain bundle/SN provides a clean back-The question of how to model a disease whose etiology remains unknown is difficult. While the strengths ground devoid of host striatal innervation to unambiguously evaluate DA cellular replacement strategies such of animal models can help to characterize the nature of the human disease, the weaknesses can sometimes pro-as fetal nigral grafts or stem cell implants. In contrast, intrastriatal 6-OHDA injections model an earlier state pel science down unproductive roads. When assessing the importance of a model for PD, it is critical that it of human dopamine insufficiency (95). This incomplete level of nigrostriatal degeneration can be utilized for succeed in accurately mimicking critical aspects of the evaluating both neuroprotection and regeneration experi-easy delivery, 6-OHDA has been used in nonhuman primates to assess the efficacy of neuroprotective strategies ments. Unilateral lesions, employing this and other DA neurotoxins, have been particularly useful in allowing (31) , cell transplantation (6) , and neuroregenerative therapies (31) . The role of primates in the evaluation of for analysis of specific behavioral tasks in lesioned animals such as rotational behavior. Following unilateral these novel therapies will be discussed in more detail later in this review. lesions, asymmetrical rotation can be observed spontaneously in rats, or in response to dopaminergic drugs 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine such as amphetamine, apomorphine, and levodopa (30, 52) . This rotational analysis has been important for the First discovered to produce parkinsonian effects in human drug users (63), 1-methyl-4-phenyl-1,2,3,6-tetra-behavioral quantification of lesion severity as well as providing a measurement of therapy-induced recovery.
hydorpyridine (MPTP) targets dopaminergic neurons in the brain. MPTP is taken up by astrocytes of the central Unilateral lesions have also provided a built-in control represented by the intact contralateral hemisphere. This nervous system and converted to its metabolite MPP+ by monoamine oxidase B. MPP+ is then taken up by has been particularly useful in nonhuman primate experiments where, like with humans, individual variation can DA neurons where it interrupts complex I of the electron transport chain, eventually leading to the death of the be so striking.
A major focus of PD research in recent years has cell via metabolic dysfunction (105). MPTP has been used in a number of species to mimic been the examination of nondopaminergic systems affected in human patients. Recent research has attempted the nigrostriatal degeneration observed in human PD (96) . Mice have provided a reasonable small-animal to determine the time course of extranigral pathology in relation to the classically described nigral degeneration. model for MPTP toxicity. However, while mice show neurotoxic responses to MPTP treatment and are often Braak and coworkers (17) have used Lewy body formation and α-synuclein aggregation to postulate that the used for convenience and low costs, the dose of toxin necessary to create a sufficient lesion is much larger pathology of PD begins in the olfactory bulb and caudal brain stem. From the caudal brain stem, the disease than that needed in primates. Mice can also show spontaneous recovery of function following MPTP treatment progresses rostrally to eventually include the substantia nigra. These findings confirm the progressive nature of (74). Rats are relatively insensitive to MPTP toxicity, with most strains showing complete insensitivity. This PD, with pathology beginning in the brain stem and moving rostrally. This progression and pathological direc-is unfortunate as they have a superior behavioral repertoire with which to analyze movement deficiencies rela-tionality, seen in the human disease, is not represented in the 6-OHDA model, which produces a regionally se-tive to mice. These shortcomings of rodent models are notably absent from the primate MPTP model. Monkeys lective lesion and begins to show degenerating neurons within 24 h and complete lesions within weeks (98).
show a high sensitivity to MPTP, rendering high doses unnecessary, and respond to lesions with quantifiable These findings, as well as clinicopathological studies, further suggest that an optimal animal model of PD must cellular and behavioral deficits remarkably similar to those of human patients. These qualities have made take into account the disruption of nondopaminergic systems in addition to mimicking the loss in the nigrostria-MPTP arguably one of the best and most utilized primate models for PD. tal pathway. While 6-OHDA's preferential toxicity to catecholaminergic neurons makes it a useful tool for se-MPTP can be delivered systemically via intraperitoneal (IP), subcutaneous (SC), intravenous (IV), or intra-lectively analyzing components of the nigrostriatal pathway, its ability to mimic the dysfunction of other brain muscular (IM) injections to create a bilateral lesion. Bilateral lesions can be particularly useful for appropri-areas affected in the human disease is limited. Both serotonergic and cholinergic systems remain intact in 6-ately modeling movement pathology, as they result in symptoms such as catalepsy, akinesia, and problems ini-OHDA-lesioned animals despite their obvious disruption in human PD patients (98). Also problematic is the ab-tiating movement like those observed in human PD. However, the morbidity of severely parkinsonian ani-sence of α-synuclein inclusions, including Lewy bodies, a hallmark pathology of PD, in 6-OHDA-lesioned ani-mals following systemic administration can be quite high if they are not nutritionally maintained (96) . Addi-mals. The lack of these inclusions suggests a failure of the model to mimic the pathogenesis of the disease, sug-tionally, following systemic administration, MPTP is excreted for several days by treated animals, causing gesting therapies based upon success in this animal model may face complications in human clinical trials. potential hazards for animal caretakers (96) . MPTP administration can be either acute, in which a relatively Again, while 6-OHDA has been used most extensively in rodents, it has had its place in nonhuman pri-high dose is given within a short period of time, or chronic, where smaller doses are given for an extended mate experimentation. Due to its selectivity and relatively period of time. Acute administration typically results in systemic injections with a much smaller dose of neurotoxin. larger cell loss modeling a later stage of PD, while chronic administration results in more moderate loss re-One study has looked at the effects of delivering MPTP via an initial unilateral ICA injection, followed sembling the middle stages of human PD (91) . Table 1 shows patterns of dopaminergic depletion from the stria-by subsequent IV injections to rhesus monkeys (81) . The initial ICA injection allowed for the development of a tum and TH+ cell loss of the nigra of four commonly used species of monkey for systemic acute and chronic significant hemiparkinsonism without high morbidity in the animals, while the subsequent IV injections allowed administration. As the data suggest, the loss incurred from various MPTP dosing regimens can vary signifi-for the development of bilateral deficits and prevented the occurrence of spontaneous recovery. Postmortem cantly across primate species, as well as among individuals and by the animal's age.
analysis of striatal and nigral tissue confirmed large dopaminergic deficits in the striatum and nigra ipsilateral Due to the possibility of a high level of animal maintenance required following extensive bilateral lesions to the ICA injection with variable depletion in the contralateral striatum and nigra. Behavioral analysis con-subsequent to systemic MPTP administration, many researchers have chosen to deliver the toxin unilaterally firmed mild to moderate deficits in lesioned animals that positively correlated with the amount of contralateral via the intracarotid artery (ICA) injection. First described by Bankiewicz and collegues (10), ICA lesion-striatal dopamine depletion and nigral cell loss incurred. This type of bilateral lesions with preferential degenera-ing involves a more invasive surgery requiring animal anesthetization; however, unilaterally lesioned animals tion to one hemisphere models in some regards hemispheric biases observed in human parkinsonian patients. show much less morbidity requiring less postoperative care for researchers. Additionally, a smaller dose of While the toxic effects of MPP+ are limited primarily to dopaminergic cells, there does appear to be some dys-MPTP can be delivered to achieve the same effect as would be needed systemically so the hazards to the ani-function in MPTP-treated animals to other neurotransmitter systems known to play a role in PD. In one mal caretakers are markedly reduced (96) . While it has been shown that ICA injections can result in small le-of the first articles to demonstrate parkinsonian-like effects following MPTP administration in the rhesus sions to the contralateral hemisphere (81), it remains relatively uninjured and may serve as a built-in control, monkey, decreases in metabolites of norepinephrine, serotonin, and dopamine were observed (20) . Unlike 6-particularly appealing in primates, who again show high levels of individual variation. Unilateral lesions also OHDA, MPTP exposure has also been shown to result in the expression of α-synuclein in some primate spe-allow for analysis of rotational behavior of animals to measure the severity of lesions and behavioral recovery.
cies. In a study looking at MPTP-treated baboons (P. anubis) (58) , cytoplasmic accumulation of α-synuclein To date, ICA MPTP administration has been primarily used in the rhesus monkey and exclusively in old world was identified in degenerating nigral neurons but did not fully represent Lewy bodies observed in human patients. monkeys. Table 1 shows dosing regimens and corresponding TH+ nigral cell loss and striatal dopamine A recent study looking at lesioned squirrel monkeys found that at 1 week post-MPTP administration, α-sydepletion levels in rhesus monkeys following ICA MPTP injection. As the data suggest, ICA administration nuclein mRNA was significantly elevated, and that at 1 month, α-synuclein protein was seen in nigral cell bod-provides a more comprehensive lesion than achieved with ies (97) . Additionally, administration of MPTP in the neurons independent of the dopamine transporter (DAT) (100). However, despite its global effects on mitochon-vervet monkey is the only model to have reproduced the resting tremor so recognizable in human PD (117) .
drial respiration, like in human PD, cell loss is seen primarily along the nigrostriatal dopamine pathway. While acute treatments of MPTP fail to model the progressive nature of PD, chronic MPTP dosing does a no-
The rotenone model mimics both the cellular and behavioral deficits observed in human PD, with animals tably better job of mimicking the gradual loss of nigrostriatal function. Following low-dose chronic MPTP showing selective degeneration of the nigrostriatal pathway and the behavioral deficits observed in PD patients. administration, PET studies performed 6 months following cessation of toxin delivery found significantly simi-Following chronic systemic administration of rotenone, degeneration can occur over a matter of months (39) . lar patterns of dopamine uptake site degeneration in MPTP-treated primates and human PD patients (18) . While A particular advantage of the model is the presence of ubiquitin-and α-synuclein-positive inclusions in the ni-this model appears to represent a progressive model of PD, chronic exposure that uses less toxic doses of MPTP gra of lesioned rodents (24) . Additionally, because it appears to inhibit complex I across neuronal subtypes, the is often associated with spontaneous recovery in some species of primate. Marmosets treated with chronic rotenone model mimics dysfunction in other neurotransmitter systems associated with human PD in a manner doses of MPTP showed a complete return to normal dopamine levels by 8 weeks following cessation of toxin superior to that seen with 6-OHDA or MPTP. Rotenone crosses the blood-brain barrier, allowing for systemic exposure (2) . Vervet monkeys displaying initial moderate parkinsonism failed to exhibit a stable PD pheno-administration of the compound via IP, IV, or IM injection. However, this bilateral lesion is particularly trau-type, as opposed to those with initially severe symptoms whose phenotype remained much more stable (28,116).
matic to the animals, resulting in high morbidity and requiring extensive postlesion care. This morbidity can One avenue of PD research where the primate MPTP model has been invaluable is in the evaluation of levo-be partially avoided by the unilateral intranigral method of administration (103) . dopa-induced dyskinesias (LIDs). Severely disabling dyskinesias develop following prolonged L-DOPA ther-Perhaps the greatest disadvantage of the rotenone model is the extensive variability of rotenone toxicity apy in human patients and have served as the major limitation of pharmacologic treatment. Particularly useful among individuals, even rodents. Where some animals show extensive deficit following administration, others is the speed at which MPTP-lesioned primates develop dyskinesia following L-DOPA treatment. Unlike hu-fail to develop lesions. In a recent study looking at the consequence of 21-day exposure to rotenone, 46% of mans, where dyskinesias can take years to decades to develop, the squirrel monkey begins manifesting dyski-the animals showed no cellular pathology in response to chronic low-dose exposure (2 mg/kg/day for 21 days), netic behavior within days, making the time frame for experimentation extremely manageable (50) . In ma-46% showed diffuse decreases in striatal TH immunoreactivity (IR), and only one animal showed focal cellular caque monkeys, dyskinetic behaviors develop at times varying from days to months. While the rat 6-OHDA loss (124) . A similarly designed study by the same group determined that while chronic low-dose rotenone model has been used successfully to address molecular and cellular questions about the causation of LIDs, the treatment failed to produce TH-IR losses in the striatum, motor deficits consistent with parkinsonian symptoms phylogentic disparity between rodents and humans has given rise to caution about the predictive abilities of this did develop; however, the loss of striatal TH-IR across doses did not correlate with motor behavior in individual model. This is in contrast with primate dyskinesia studies, where there is a reasonable similarity of anatomy, rats (35) . The extensive variability observed in individual re-physiology, and a critical parallel in the phenotype between monkey and human L-DOPA-induced involuntary sponses to rotenone remains a major obstacle to its reliable use in primate studies. Primate experimentation is movements, thus allowing for a more confident transference of monkey data to clinical trials.
particularly hindered by limits on sample size. Variability in response, coupled by low sample sizes, makes ap-Rotenone propriately powered monkey studies using rotenone somewhat impractical. As of the time of this review, no The organic pesticide, rotenone, also exerts its neurotoxic effects through inhibition of complex I of the elec-journal publications currently exist using a primate model of rotenone; however, there is an increasing num-tron transport chain. However, unlike its counterpart MPTP, rotenone toxicity is not limited to dopaminergic ber of abstracts and unpublished data looking at rotenone's effects on nonhuman primates, suggestive of the cells. Following systemic exposure to rotenone, complex I is globally inhibited throughout the central nervous increasing interest in the development of a rotenone primate model of PD. However, all of these primate studies system (86) , suggesting that rotenone is taken up by are preliminary and all are underpowered to provide use-man disease. However, with the development of viral vectors for the delivery of therapeutic genes to the CNS ful data with reasonable rigor.
has come the opportunity to create a genetic primate Paraquat and Maneb model of PD through site-specific overexpression of the α-synuclein gene (54) . As a prelude to primate studies, Administration of the pesticide paraquat (PQ) has also served as an animal model of PD. PQ (1,1′-dimethyl-Lewy body-like inclusions and a progressive loss of dopaminergic neurons were observed when human α-synu-4,4′-bipyridinium) is initially converted in CNS neurons via diaphorase activity to a PQ cation. This compound clein was overexpressed with an adenoassociated viral vector in the nigrostriatal pathway of rats (53) . A similar is then reoxidized to form the parent compound as well as superoxide radicals. This continual redox cycling is study found PD pathology in rats receiving lentiviral delivered α-synuclein (68). Rats showed a 35% reduction believed to contribute to cell toxicity via oxidative stress, and the exhaustion of intracellular NADPH (120).
in nigral TH expression when human mutant protein was expressed but no reduction when rat α-synuclein was Paraquat is most commonly administered via systemic injections; however, it is sometimes administered orally expressed, suggesting that the overexpression of the protein alone is not solely responsible for cellular degenera-or transdermally, as these are the means of most human contamination. Administration can be either acute or tion (68). A similar pattern of cellular dysfunction was observed in a primate model (54) . Following adenoas-chronic, although due to PQ's relatively low lethal dose, experimentation often favors chronic delivery.
sociated viral vector delivery of mutant human αsynuclein, marmosets showed a 32-41% reduction in do-Chronic exposure to the fungicide, manganese ethylene-bis-dithiocarbamate (maneb), has also been linked paminergic neurons of the substantia nigra, α-synucleinpositive inclusions, and dystrophic neurites. Addition-to the development of parkinsonian symptoms. While its exact mechanism of toxicity is not fully understood, it ally, monkeys showed head positioning bias and rotational asymmetry consistent with that observed in other is believed to play a role in dopaminergic degeneration also through the promotion of oxidative stress (12,123).
toxin-induced models of PD (54) . This first report of a nonhuman primate genetic While eliciting their neurotoxic effects via different mechanisms, researchers have found that combination model is particularly appealing, as it addresses the role of Lewy body formation in PD, a facet that is not pres-treatment of both paraquat and maneb can result in exaggerated dopamine cell loss and behavioral deficits when ent in other models. The fact that this is a relatively progressive model of PD, extending as long as 16 weeks compared to either treatment alone. Rodent studies have provided evidence for nigral degeneration and DA in the marmoset (54), is a significant advance over many more acute toxin models. While rotational analysis and depletion following PQ and maneb exposure. Mice injected with PQ (10 mg/kg) and maneb (30 mg/kg) twice postural dysfunction suggest that some behavioral correlates with human PD exist, it remains to be fully investi-weekly for 3 weeks showed significantly reduced striatal TH protein levels (10-17%) and significant nigral cell gated how accurately this model actually mimics behavioral dysfunction reminiscent of PD. Further, the effects loss (25-47%) compared to age-matched controls (118). Additionally, Lewy body-like α-synuclein inclusions of transgenic overexpression of α-synuclein on other neurotransmitter systems affected in PD remain unknown. have been observed in PQ + maneb-treated mice (71). Maneb administered during gestation in mice has been shown to result in an increased response to PQ when NOVEL THERAPIES FOR PARKINSON'S: delivered in adulthood (11). As these compounds are of-THE ROLE OF NONHUMAN PRIMATE STUDIES ten used in combination in agriculture, this evidence for Therapies for PD have classically focused on the resa "multihit hypothesis" of PD is a cause for some alarm.
toration of balance between dopamine and acetylcholine The central effects and utility in creating a primate within the basal ganglia. However, novel technologies PD model of PQ and maneb has yet to be characterized. such as cell replacement and gene therapies have offered However, a growing body of rodent research (12,118), the promise of better treatment options for PD patients. and reports of human contamination (34, 122) have re-Nonhuman primate models of PD, particularly the 6searchers looking to determine the appropriateness of OHDA and MPTP models, have played a significant PQ and maneb toxicity as a model for PD.
role in assessing the efficacy of these treatment regimens and expanding patient options.
Genetic Models
Mutations in the α-synuclein gene are associated with Trophic Factors: GDNF familial PD (78) , and α-synuclein inclusions in the nigra are present-day hallmarks of PD pathology. Toxin mod-Glial cell line-derived neurotrophic factor (GDNF), expressed in the substantia nigra (23,59) and striatum els have failed to replicate this critical aspect of the hu- (59) , is a potent trophic factor for dopaminergic neurons.
tive effects of GDNF (40) . MPTP-treated rhesus monkeys receiving chronic controlled GDNF infusions to the lat-Postmortem brains from PD patients have been reported to show a decreased level of striatal GDNF (37), sup-eral ventricle via programmable pumps showed bilateral increases in the size and TH expression of nigral neu-porting the idea that increasing GDNF expression therapeutically in the striatum and substantia nigra may en-rons. Additionally, an increase in dopamine metabolites was observed in the striatum and pallidum. The lesioned hance dopaminergic neuronal activity, thus alleviating cardinal parkinsonian symptoms. Viral vectors as well hemisphere demonstrated increased dopamine levels in the periventricular striatum and the globus pallidus as as continuous infusion have been used to introduce GDNF into various brain locations in parkinsonian pri-well as fivefold increase in TH+ fiber density in the periventricular striatal region (40) . The increased TH+ mates with the hope that, unlike pharmacological dopamine replacement or deep brain stimulation, treatment neuronal fiber density observed in GDNF-treated animals suggests GDNF may be involved in reestablishing with exogenous GDNF may be neuroprotective. Dosage level, time course of administration, and location of striatal dopaminergic innervation. These results demonstrate that GDNF, in addition to being neuroprotective, GDNF delivery are crucial determining factors for the success of GDNF delivery. Intraventricular administra-may also be neurorestorative. It is of interest that while GDNF delivery has shown neuroprotective effects in tion of GDNF on a monthly basis failed to provide clinical benefit, and was associated with significant side ef-toxin models of PD such as 6-OHDA and MPTP, it has failed to produce these effects in an α-synuclein genetic fects (56, 79) . However, viral vector delivery of the trophic factor has been shown to provide consistent model of PD. In a recent study, rats pretreated with lenti-GDNF failed to prevent neurodegeneration follow-GDNF expression with only minor toxicity. Lentiviral vector delivery of GDNF to the striatum and substantia ing mutant α-synuclein overexpression, despite robust GDNF expression (69) . What these finding might mean nigra of MPTP-lesioned rhesus monkeys reversed functional deficits and completely prevented nigrostriatal de-for GDNF's ability to prevent degeneration in human idiopathic PD remains to be seen. generation (11). Lenti-GDNF increased the size and number of TH-positive neurons within the substantia ni-Grafting gra, increased TH mRNA expression in neurons, and increased dopamine, dopamine metabolites, and dopamine
In 1917, Elizabeth Dunn, an anatomist from the University of Chicago, first reported partial survival of brain markers in the striatum. Additionally, increased fluorodopa uptake in the striatum of lenti-GDNF-treated ani-tissue transplanted from one newborn rat to another. While little was done in the field of neural grafting be-mals was observed. While typically aged monkeys show a decrease in TH-IR nigral neurons when compared to tween 1917 and 1970, the mid-to late 1970s saw a resurgent interest in the use of grafted cells to treat human their younger counterparts, lenti-GDNF aged monkeys were shown to have a number of TH-IR neurons similar disease, PD in particular. While Dunn first recognized that transplanting embryonic tissue was key to graft sur-to that in young adults (11). Other viral vector systems have been successfully used to deliver GDNF to parkin-vival, the painstaking work of researchers in Sweden and the US in the mid to late 1970s began to unveil sonian primates. A recombinant adeno-associated viral vector (rAAV) was used to deliver GDNF to the sub-the concept that grafted cells could potentially serve to therapeutically replace those lost to disease (15,46,47, stantia nigra and the striatum of marmoset monkeys 4 weeks prior to 6-OHDA lesions of the nigrostriatal bun- 84, 85, 111) . In 1979, two groups, one lead by Anders Björklund and Ulf Stenevi and a second lead by Bill dle (31) . rAAV-GDNF monkeys demonstrated reduced disability scores as well as reduced head position bias,
Freed and Barry Hoffer, demonstrated that grafted fetal dopamine neurons could provide therapeutic benefit in both indicative of protection against 6-OHDA lesions. Additionally, animals demonstrated partial to complete a rat model of PD, thus providing hope that grafted tissues could be similarly used in human PD patients. protection as assessed by amphetamine and apomorphine rotational analysis, again suggesting a protective Just as fetal grafting began to offer therapeutic promise, the controversy surrounding fetal tissue use com-effect of GDNF (31) .
GDNF's ability to provide neuroprotection, prior to pelled researchers to explore less controversial tissue sources. The best studies of these are with the chromaf-and immediately following MPTP and 6-OHDA administration, led to the hope that it would show equal suc-fin cells of the adrenal medulla. In 1984, Morihisa and colleagues (75) reported the first grafting of autologous cess in providing neural restoration following lesions. In contrast to neuroprotective studies in which lenti-GDNF adrenal chromaffin cells into nonhuman primates. Their experiment consisted of parkinsonian rhesus monkeys was administered 1 week postlesions, one study delivered GDNF 3 months post-MPTP administration to dis-receiving either adrenal cell grafts or embryonic nigral tissue grafts. They reported a modest survival of adrenal tinguish between the neuroprotective and neurorestora-medulla tissue (10-300 cells per animal) in all four ani-tal designs from the nonhuman primate studies. Both double-blinded trials grafted the cells into the postcom-mals tested. This study is difficult to evaluate because the fetal tissue, which survives robustly under most con-missural putamen. There were good theoretical reasons to do so. The loss of striatal dopamine is greatest in the ditions, failed to survive in this study. Thus, it appears that the conditions for survival were suboptimal, making postcommissural putamen and this region of the striatum is intimately connected to motor cortex. However, it is it difficult to assess the true measure of graft viability. Even so, later studies done independently by Plunkett, notable that that nonhuman primate studies that were most successful grafted the cells into the caudate nu-Bankiewicz, and colleagues (93) and Fiandaca and colleagues (33) demonstrated that adrenal chromaffin cell cleus. Indeed, Taylor (115) and colleagues demonstrated that the location of nigral grafts within the primate stria-do not survive well when grafted to parkinsonian monkeys. These studies further demonstrated that although tum influenced the level of functional recovery observed. Comparing nigral grafts to the caudate, putamen, grafts of adrenal chromaffin cells did not survive, they induced a sprouting of host-derived dopaminergic fibers.
non-DA grafts, and sham "needle-pass only" surgeries, they found that the grafts delivered to the caudate resulted The poor viability of the graft is likely due to the immunogenic endothelial cells and nonchromaffin cells that in the most significant benefit. Additionally, Annett et al. found caudate nigral grafts significantly improved are grafted with the adrenal medulla. When the chromaffin cells are purified using a Percoll gradient, robust amphetamine-induced rotational bias in the 6-OHDAlesioned marmoset (5) . Furthermore, single-cell record-chromaffin survival is seen following grafting into rodents and nonhuman primates (104) . Prior to and con-ings of the primate caudate and putamen preceding earliest movement-related muscle activity show electrical comitant with these primate studies, a number of clinical trials using adrenal medulla grafts were attempted; how-activity in the caudate and putamen (45), suggesting that both may be critical targets for neural replacement. ever, these resulted in transient behavioral benefits and high morbidity (7, 9, 38, 51, 64, 67, 90) . Postmortem studies Not only did these double-blinded trials fail to demonstrate uniform functional benefit, the induction of a confirmed the nonhuman primate experiments; graft survival was poor and the degenerating grafts induced a serious new side effect called graft-induced dyskinesias was noted. The phenotype of these dyskinesias was gen-host-derived sprouting response (44,55).
As attempts to utilize adrenal cells in therapeutic erally similar to diphasic dyskinesias in that they consisted of stereotypic, rhythmic movements (although other transplants for PD failed, successful trials showing the survival of grafted embryonic nigral dopamine neurons hyperkinesias and dystonias were sometimes apparent). They also were preferentially localized to either the and behavioral improvement in nonhuman primates began to emerge (8, 107, 108) . The successful storage and lower (83) or upper (70) extremities. What was troubling was that these dyskinesias persisted even after with-engraftment of human fetal nigral tissue in rodents and nonhuman primates (99) set the stage for clinical trials.
drawal of antiparkinsonian medication and were sufficiently disabling that many of the patients underwent After the success of a number of open-label embryonic transplant trials (19, 41, 43) , the National Institutes of surgical implantation of deep brain stimulators in an effort to control these abnormal movements. Why didn't Health sponsored two prospective randomized doubleblinded trials that tested with great rigor the hypothesis preclinical studies predict this side effect? One strong possibility is that no study ever grafted embryonic nigral that fetal nigral grafts would be safe and efficacious in patients with PD. One trial lead by Curt Freed and Stan neurons into the striatum of levodopa-primed, dyskinetic nonhuman primates. This represents an unfortunate failure Fahn (36) used patient reports on activity of daily living as a primary endpoint while the trial lead by Warren to properly use the nonhuman primate model, because all patients receiving fetal transplants have been on antipar-Olanow (83) used the Unified Parkinsonian Disease Rating Scale in "off" as a primary endpoint. Both studies kinsonian medication and suffer from dyskinesias prior to grafting. Thus, it is not sufficient just to have a valuable failed to show significant improvement in their primary endpoints. This overall lack of significance occurred in model like the MPTP-treated monkey, as the failure to use it properly might lead to disastrous results. spite of excellent graft survival and innervation as measured by fluorodopa positron emission tomography and A number of studies have used parkinsonian monkeys to better define the parameters that may be used postmortem analyses. It should be noted that secondary analyses revealed that younger patients (36) or patients for clinical study. One parameter is the age of the transplanted tissues (6, 109) . In 1997 Annett and colleagues with less severe disease (83) did improve and this procedure may be best suited to specific subgroups of PD added a temporal profile to the problem of grafting into the basal ganglia (6) . While younger donors appear to patients. It remains unclear as to why these trials failed to show uniform efficacy in all patients. However, it is provide more TH+ neuronal survival and significantly reduce the number of amphetamine-induced rotations, clear that the clinical trials did not mimic the experimen-they also are associated with a higher incidence of graft-keys. These transplanted cells functioned as DA neurons and improved parkinsonian behaviors 12-14 weeks induced dyskinesias. Older donor neurons from the ventral mesencephalon show fewer incidences of these ab-posttransplantation (114) . normal behaviors, but do not survive as well as those Deep Brain Stimulation from younger donors.
In addition to the graft location and donor tissue age, An association between subthalamic nucleus (STN) activity and movement has been demonstrated in Afri-researchers have also examined the amount of tissue optimal for graft survival and behavioral recovery. To ob-can Green monkeys whose neurons of the STN responded to passive movement, light touch, and muscle serve how graft distribution affected outcome, Sladek and colleagues placed increasing amounts of fetal nigral palpation (121). The STN is believed to be disinhibited in PD, which is thought to lead to the pathological ex-tissue into parkinsonian vervet monkeys (110) . It was found that when the amount of tissue transplanted was citement of its targets, the globus pallidus internal (GPi) and substantia nigra pars reticulata (SNpr), resulting in doubled (macrografts) cell survival was not similarly doubled. Further, multiple smaller "micrografts" were the characteristic symptoms of PD (27) . The role of the STN in PD came to the forefront with the discovery that found to produce greater elevations of striatal DA throughout the caudate and showed greater behavioral high-frequency stimulation of the STN (HFS-STN) was an effective therapy for late-stage PD patients, relieving efficacy relative to in macrografted animals. These nonhuman primate studies support the concept originally many classic parkinsonian symptoms including tremors (87) , postural instability (61, 66, 94, 101) , akinesia, and ri-demonstrated in rats by Guido Nikkah and coworkers (76, 77) . gidity (65). Both unilateral and bilateral STN stimulation have been effective in reducing PD symptoms in If cell replacement strategies are to ever become therapeutically relevant, we will need a standardized, readily rodent and nonhuman primate models as well as in human patients. Deep brain stimulation of the STN is cur-available tissue source. Stem cells are the hope for this source. One particular advantage to embryonic stem cell rently an effective treatment option for late-stage PD patients. (ESC) transplantation is the ability to manipulate grafted cells to express therapeutic agents. Human neural pro-Although the specific molecular mechanisms underlying the effects of HFS-STN remain unknown, it is hy-genitor cells (hNPCs) can differentiate into both astrocytes and neurons following transplantation in the ner-pothesized that its inhibition of the STN leads to a decrease in glutamatergic output to the GPi (73) as well as vous system and can migrate throughout the striatum (80, 112, 114) . Recently, hNPCs from fetal brain tissue decreased cortical glutamate input to striatum (22) , thus normalizing the glutamate imbalances observed in PD. were genetically modified to release glycosylated GDNF in vitro under the control of an inducible promoter (113) .
However, it has been observed that HFS-STN actually increases mean firing rate of GPi neurons and changes These cultured hNPC-GDNF cells were transplanted into both rat and aged monkey brain and demonstrated their firing pattern from spontaneous irregular to regular (42), suggesting that HFS-STN may actually excite the survival and GDNF expression in both models, for up to 3 months in the aged primate. This work represents a STN in MPTP-lesioned primates. These apparently contradictory findings can be resolved when the intensity of promising integration of stem cell and gene replacement therapies for the treatment of PD.
HFS-STN is considered. While low-intensity HFS ultimately results in decreased SNpr activity, high intensity While ESCs represent an attractive alternative to fetal tissue for engraftment into parkinsonian brains, control-ultimately results in an increase in SNpr activity (72). This suggests HFS-STN decreases STN activity via ex-ling ESC differentiation has been a major concern in regards to their clinical use. The "stromal cell-derived citation of presynaptic GABA fibers, and increases GPi activity by exciting postsynaptic glutamatergic fibers. inducing activity" (SDIA) method of differentiation uses SDIA-expressing mouse stromal cells (PA6 cells) to in-
The motor cortex has also been examined as a potential therapeutic target for brain stimulation in the MPTP duce primate ESCs lacking BMP-4 expression to become neural precursors and postmitotic neurons (104) .
primate model. HFS of the motor cortex was shown to reduce both akinesia and bradykinesia and increase the Neural progenitors are then cultured from monkey ES cells and expanded as neurospheres in order to obtain metabolic activity of neurons in the supplementary motor area (SMA). This stimulation also led to normaliza-DA precursors. Induction of DA neurons is enhanced by treatment with FGF20, a member of the FGF family that tion of the mean firing rate of neurons within the GPi and STN and a reduction of synchronized oscillatory is exclusive to the substantia nigra and reportedly has protective effects on DA neurons (13). This method has neuronal activity in both of these structures (26) . While deep brain stimulation is certainly a valuable been used to obtain midbrain DA neurons that were then transplanted into MPTP-lesioned cynomologus mon-therapy for late-stage parkinsonian patients, a full under-standing of the mechanism of action of this powerful behavioral, and cognitive similarities to humans, primates are ideally suited to mimic the particulars of idio-technique remains to be elucidated. The particulars of determining ideal frequency, intensity, and localization pathic PD not provided by models of lower phylogeny. Similarities in genotype have allowed for better analysis of stimulation will be critical to the full utilization and optimization of this treatment.
of the role of genetic dysfunction in PD. The homology between human and primate brain anatomy and physiol-CONCLUSION ogy has been particularly important, with monkeys pos-The Primate Model and Parkinson's Disease sessing a striatum segregated by an internal capsule and related circuitry not present in the rodent model. Behav-Basic animal research has allowed for advances in ioral and cognitive similarities have allowed for the medicine that could not have been imagined 100 years analysis of complex facets of human PD, not possible ago. Attempting to understand disease and develop in other models. The similarity of basal ganglia motor means to improve human health and quality of life has programs in humans and nonhuman primates has prorequired biomedical research efforts on many levels.
vided profiles of behavioral dysfunction that are unmis-Advancements have often importantly progressed from takable analogs seen in human PD, which has allowed more simple models to the more complex primate incredibly accurate and predictive modeling of human model. The availability of primate models has undoubtdysfunction. edly been critical in advancing the understanding of basic primate biology necessary for therapeutic benefits in Weaknesses of the Primate Model PD and wide range of human conditions. While this
As this review has demonstrated, research to date has model has fundamental importance in biomedical rebeen unable to produce a single animal model that accusearch, practical factors need to be considerd when rately portrays all of the cellular and behavioral deficits choosing to do research in primates, such as the choice or progressive nature that is hallmark of human PD. of which nonhuman primate and which of the models of Current models have done a particularly poor job of re-PD to use. Typically smaller species of primate are seproducing the nonnigrostriatal dysfunctions observed in lected to reduce the cost of housing and handling re-PD. It is notable that complaints made by PD patients quired for maintenance; however, as the phylogenetic often involve dysfunction in nondopaminergic systems distance between humans and the primate species chosen rather than the motor difficulties that research remains increases so too does the behavioral, physiological, and so focused on. It will most certainly fall to primate subanatomical differences. Also of importance is the spejects to accurately model these more complex and socies ability to reproduce well in captivity. As social aniphisticated dysfunctions. Also poorly represented by mals, the heath and reproductive viability of primates current models, and of critical importance in addressing can be particularly difficult to maintain. Finally, the speneuroprotective strategies, is the progressive nature of cies must be nonendangered to be considered. These cri-PD. Chronic MPTP administration in primates remains teria are met in the most frequently utilized primate one of the few models addressing this progression. models such as, the common marmoset (Callithrix jac-Additionally, primate-specific obstacles exist. Spechus), the macaque (Macaca mulatto, Macaca fascicucies, such as the marmoset, that fit the criteria for houslaris), the vervet (Chlorocebus), and the squirrel moning and maintenance required for primate experimentakey (Sairi). tion can also present the difficulty of having a smaller It has been the aim of this review to highlight some and less developed brain than other nonhuman primates. of the more critical advantages and disadvantages asso-As the sophistication of the species declines it is likely ciated with current models and their various modes of that its predictive clinical value does too. Also, approadministration as well as to introduce some of the novel priate environments for living and breeding are much models currently being developed that promise to shed more challenging and costly for the primate than with light on aspects of PD presently underaddressed by curother model organisms. Finally, increased variation rent toxin models. When designing experiments and inamong individuals and the necessity of smaller sample terpreting data, it is critical to understand the strengths sizes in primate studies can often complicate statistical and weaknesses of the model and species employed, as analysis. However, despite these disadvantages, prithe balance of these will ultimately be the determinate mates remain the nearest link between basic and clinical of the predictive value of the research. sciences, and the greatest hope for effectively modeling Advantages of the Primate Model and treating human disease. Nonhuman primate models have proven to be an in-Insights Provided by the Primate Model valuable final, preclinical tool in the understanding of human PD and in the evaluation of therapeutic interven-While it is apparent from this brief review that no one model of PD is ideal, it is important to note that tions. With strong genetic, anatomical, physiological, 
